IL1B and posterior cortical atrophy: Several types of molecules are offered to avoid the biological effects of IL-1β and Anakinra, an IL-1β receptor agonist, used for the treatment of systemic inflammatory disorders, has been proposed as a therapeutic strategy for PCa treatment [16].